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Astract
Background: Cutaneous injection-related infections (CIRI) are a primary reason individuals who inject drugs (IDU) are 
hospitalized. The objective of this study was to investigate determinants of hospitalization for a CIRI or related 
infectious complication among a cohort of supervised injection facility (SIF) users.
Methods: From 1 January 1 2004 until 31 January 2008, using Cox proportional hazard regression, we examined 
determinants of hospitalization for a CIRI or related infectious complication (based on ICD 10 codes) among 1083 IDU 
recruited from within the SIF. Length of stay in hospital and cost estimates, based on a fully-allocated costing model, 
was also evaluated.
Results: Among hospital admissions, 49% were due to a CIRI or related infectious complication. The incidence density 
for hospitalization for a CIRI or related infectious complication was 6.07 per 100 person-years (95% confidence intervals 
[CI]: 4.96 - 7.36). In the adjusted Cox proportional hazard model, being HIV positive (adjusted hazard ratio [AHR] = 1.79 
[95% CI: 1.17 - 2.76]) and being referred to the hospital by a nurse at the SIF (AHR = 5.49 [95% CI: 3.48 - 8.67]) were 
associated with increased hospitalization. Length of stay in hospital was significantly shorter among participants 
referred to the hospital by a nurse at the SIF when compared to those who were not referred (4 days [interquartile 
range {IQR}: 2-7] versus 12 days [IQR: 5-33]) even after adjustment for confounders (p = 0.001).
Conclusions: A strong predictor of hospitalization for a CIRI or related infectious complication was being referred to 
the hospital by a nurse from the SIF. This finding indicates that nurses not only facilitate hospital utilization but may 
provide early intervention that prevents lengthy and expensive hospital visits for a CIRI or related infectious 
complication.
Background
Cutaneous injection-related infections (CIRI), which
include cellulitis and abscesses, are among the primary
causes of hospitalization among individuals who inject
drugs (IDU) [1-4]. Hospitalizations due to CIRI carry
considerable economic burden [3,5,6]. Complications of
CIRI that are more likely to require hospitalization
include, but are not limited to: osteomyelitis [7], bactere-
mia and sepsis [8,9], endocarditis [10,11], septic arthritis
[7,12], ulcer [9], thrombophlebitis [13,14] and myositis
[9].
A recent report by Hope et al. (2008) suggested that
healthcare associated costs for CIRI among IDU in Eng-
land were substantial, ranging from £15.5 million to £30.0
million per annum [5] ($27.1 to $52.4 million Canadian
dollars). In 2001, Palepu et al. reported that of the IDU
seen at St. Paul's Hospital, an urban hospital in Vancou-
ver, Canada, 35% had been hospitalized and a third of
these hospitalizations were due to a CIRI or related infec-
tious complication [1]. Hospitalization was expensive
with hospital utilization cost per day reported to be $610
Canadian dollars (C$610) (95% confidence interval {CI}:
C$C576- C$645) [1].
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opened in Vancouver's Downtown Eastside (DTES) in
2003. Within the SIF, IDU can inject pre-obtained drugs
under the supervision of nurses. Individuals visiting the
SIF are provided with sterile injecting equipment and
emergency intervention in the event of an overdose, as
well as primary medical care and addiction treatment,
either on site or through referral. While several studies
have pointed to the positive impact of the SIF on public
disorder [15], HIV risk behaviour [16], management of
overdose [17,18] and use of addiction treatment [19], its
role with regard to hospitalization for CIRI remains
unknown. However, recent research highlights that CIRI
are a medical issue of concern among users of the SIF.
Over a two year period, 6-10 per cent of IDU had a CIRI
at time of interview [20]. In the present analysis, using
longitudinal data, we examined predictors and cost of
hospitalization for a CIRI or related infectious complica-
tion among IDU using the SIF.
Methods
Design and participants
The SIF in Vancouver is being evaluated through the Sci-
entific Evaluation of Supervised Injection (SEOSI)
cohort, which has been described in detail [21]. Briefly,
the cohort was assembled through random recruitment
of IDU from within the SIF. Random recruitment is based
on inviting users of the SIF to be referred to the research
study during random blocks of time. Among individuals
who were recruited, a venous blood sample was drawn
and an interviewer-administered questionnaire was con-
ducted at baseline and at semi-annual follow-up visits.
The informed consent agreement, obtained for all partic-
ipants, included a request to link the SIF evaluation with
administrative health databases. In Vancouver, hospitals
are equipped with a database that tracks patient admis-
sion. The SIF is also equipped with a similar database. At
the SIF, nursing care includes wound care, dressing
changes, and measuring temperature. However, there are
no physicians at the SIF. If microbiological investigation
or medical treatment, including antibiotic prescription or
intravenous antibiotic therapy is required, individuals at
the SIF must be referred to the hospital or a medical
clinic. In this study, a linkage of SEOSI participant data,
SIF data and St. Paul's Hospital inpatient data was per-
formed. St. Paul's Hospital is the major urban hospital
serving the DTES community, one of Canada's poorest
postal codes. The University of British Columbia-Provi-
dence Health Care Research Ethics Board approved the
present study.
Measurements
The start point for these analyses was enrollment into the
SEOSI cohort and the endpoint was hospitalization for a
CIRI or related infectious complication. The infectious
complications included were based on previous literature
[8,9]. The definition of the reason for hospitalization was
based on International Classification of Diseases (ICD)
10 codes on patients' hospital records and included:
abscess (G061, G062, L020, L021, L022, L024, J851), cel-
lulitis (L0300, L0310, L0311, L032, L0335, L038), osteo-
myelitis (M4620, M4625, M4629, M8617, M8618, M8661,
M8663, M8666, M8681, M8691, M8695), staphylococcal
infection 161 {(A490, A499, B956) including, septicaemia
(A410, A412, A419) and Methicillin-Resistant Staphylo-
coccus aureus (MRSA), (U000)}, endocarditis (I330), sep-
tic arthritis (M0000, M0002, M0004, M0005, M0006,
M0008, M0009), ulcer (L089, L979), thrombophlebitis
(I802, I808) and myositis (M6005, M6008). A few ICD-10
codes chosen suggest but do not require infectious etiolo-
gies (e.g., thrombophlebitis, myositis, and ulcer). The
number of events refers to a CIRI or related infectious
complication as a primary, secondary, tertiary, quater-
nary, or quinary diagnoses according to relevant ICD 10
codes unless otherwise specified.
We first examined the distribution and frequency of a
CIRI or related infectious complication. Then, we evalu-
ated length of stay in hospital among study participants
and examined this outcome as a continuous variable in a
linear model that adjusted for the following confounding
variables: age, sex, HIV serostatus and SIF nurse referral.
We then considered the cost of hospitalization, associ-
ated with CIRI, which was estimated at C$712 per hospi-
tal day, based on a fully-allocated costing model for the
province of British Columbia from 2001 [1]. This esti-
mate was updated to Canadian dollars in 2005 [22]. Fully-
allocated costing includes costs associated with nursing
care, medications, investigations, physician visits and
length of stay as well as overhead, opportunity cost of
hospital resources and a 5% depreciation of capital equip-
ment [1]. Potential healthcare savings were estimated by
multiplying the cost per day value (C$712) by the differ-
ence in number of days hospitalized among individuals
with CIRI who were referred by a nurse within the SIF
and those who were self referred to the hospital.
We investigated baseline characteristics stratified by
hospitalization or not bivariately. Using Cox proportional
hazard regression, we examined factors potentially asso-
ciated with hospitalization. Variables considered for our
analyses included: age; sex at birth (female vs. male); cur-
rent residence in DTES (yes vs. no); living in unstable
housing (yes vs. no); daily cocaine injection (yes vs. no);
daily heroin injection (yes vs. no); daily speedball injec-
tion (yes vs. no); and HIV serostatus (positive vs. nega-
tive). As used previously, unstable housing was defined as
living in a single room occupancy (SRO) hotel, shelter,
recovery or transition house, jail, on the street, or having
no fixed address [23]. Variables from the semi-annual
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last six months unless otherwise specified. We also exam-
ined whether a SIF nurse referral to the hospital was asso-
ciated with hospitalization and, if so, whether length of
stay was different given referral versus self referral. For
this task, we conducted a record linkage matching their
SEOSI identifying code to each participant's record in the
SIF database to determine nurse referral. Then, we linked
his or her SEOSI identifying code with his or her unique
personal health number to examine hospital records
prior to the censor or event date.
Variable selection was based on previously published
literature on a CIRI or related infectious complication
and hospitalization among IDU [1,5,8,9,20]. Variables
considered associated with hospitalization were analyzed
in unadjusted analyses and adjusted Cox proportional
hazard regression model. Time zero was defined as the
date of recruitment into the SEOSI study for all partici-
pants and participants not hospitalized at St. Paul's Hos-
pital were censored as of 31 January 2008. All behavioral
variables were treated as time-updated covariates based
on semi-annual follow-up data. The multivariate model
was fit using a fixed model whereby we included all vari-
ables that were statistically significant at the p < 0.05 level
in univariate analyses. All statistical analyses were per-
formed using SAS 8.0 (Cary, NC) and all p-values were
two-sided.
Results
During the study period (1 January 2004 to 31 January
2008), 1083 individuals were recruited into the SEOSI
cohort and 901 (83%) reported at least one follow-up
visit. The median age among SEOSI participants was 38.4
years (interquartile range {IQR}: 32.7-44.3) and 314 (29%)
were female. The median follow-up duration after
recruitment into the cohort was 21.4 months (IQR: 13.1-
24.6). During the study period, 99 (9%) participants were
admitted to St. Paul's Hospital, yielding an incidence den-
sity of hospitalization for a CIRI or related infectious
complication of 6.07 per 100 person-years (95% CI: 4.96 -
7.36). Among all hospital admissions among SEOSI par-
ticipants, 49% (216 of 442) were related to a CIRI or
related infectious complication. A total of 216 hospital-
ization events occurred among 99 individuals for a CIRI
or related infectious complication. Among the 99 hospi-
talized SEOSI participants, 47 received CIRI care at the
SIF during the study period. A total of 145 SEOSI partici-
pants were referred by a nurse at the SIF while 63 partici-
pants were referred and visited the ED. In addition, 115
SEOSI participants were referred but subsequently not
hospitalized. Importantly, 60% (28/47) of those who
received CIRI care at the SIF were referred to the hospital
by a nurse at the SIF and subsequently sought treatment
at the hospital. Individuals with an ED visit who were
referred by a nurse were more likely to be hospitalized
within three days (p = 0.011). Further, those who were
referred to the hospital by a nurse at the SIF were signifi-
cantly more likely to have been seen by a nurse at the SIF
for a CIRI (8 nurse visits for a CIRI [IQR: 3-16]) com-
pared to those that were not referred to a hospital (1
nurse visit for a CIRI [IQR: 0-4]) (p < 0.001). Virtually all
patients are admitted to the hospital from the Emergency
Department (ED).
Tables 1, 2 and 3 display the frequency of a CIRI or
related infectious complication. Cellulitis was the most
common reason for hospitalization. Fifteen persons had
missing data on HIV serostatus and were excluded from
analyses. Therefore, all results on HIV were based on a
sample size of 1068. Participants who had been referred
to the hospital by an SIF nurse had a significantly shorter
length of stay in hospital as compared to those who were
not referred (4 days [IQR: 2-7], 12 days [IQR: 5-33]). The
eight day reduction in the length of hospital stay remained
significant (p = 0.001) after adjustment for confounding
variables. Considering the total potential healthcare sav-
ing based on a fully allocated hospital cost per day calcu-
lation, each referral from the SIF would have resulted in a
saving of C$5,696 (IQR: C$2, 136 - C$18, 512).
The factors associated with an increased risk of hospi-
talization after recruitment into the SEOSI cohort are
shown in Table 4. In the multivariate model being HIV
positive (adjusted hazard ratio [AHR] = 1.79 [95% CI:
1.16 - 2.75]) and being referred to the hospital by a nurse
at the SIF (AHR = 5.38 [95% CI: 3.39 - 8.55]) were posi-
tively and independently associated with an increased
likelihood of hospitalization.
Table 1: Description of hospitalizations for a cutaneous 
injection-related infection or related infectious 
complication among Scientific Evaluation of Supervised 
Injection participants.
Classification† First event Total events
n (%) n (%)
n = 99 n = 216
Cellulitis 33 (33) 59 (27)
Abscess 14 (14) 26 (12)
Osteomyelitis 10 (10) 39 (18)
Staphylococcal infection 22 (22) 42 (17)
Endocarditis 9 (9) 24 (12)
Septic arthritis 7 (7) 12 (6)
Ulcer 1 (1) 6 (3)
Thrombophlebitis 1 (1) 4 (2)
Myositis 2 (2) 4 (2)
† Classification is based on International Classification of Diseases 
10 codes
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In the present study, being referred by a nurse at a SIF
was independently associated with an elevated rate of
hospitalization. Importantly, participants who had been
referred to the hospital by a nurse at the SIF had a signifi-
cantly shorter length of stay in hospital despite adjust-
ment for HIV infection and other potential confounders.
This finding indicates that nurses facilitate hospital utili-
Table 2: Distribution of hospitalizations for a cutaneous injection-related infection or related infectious complication*.
Primary diagnosis +1 +2 +3 +4 +5 +6 +7 +8 +9 +1&2 +1&4
1cellulitis 45 - 3 0 5 0 0 2 1 0 - -
2abscess 9 1 - 0 5 0 0 0 0 0 - 3
3osteomyelitis 14 0 5 - 5 0 0 0 1 2 0 1
4staph.infection 18 3 0 1 - 4 0 0 0 0 1 -
5endocarditis 12 0 1 0 5 - 0 0 0 0 0 1
6septic arthritis 8 0 2 0 1 0 - 0 0 0 0 1
7ulcer 3 0 0 0 1 0 0 - 0 0 0 0
8thrombophlebitis 3 1 0 0 0 0 0 0 - 0 0 0
9myositis 1 0 0 0 3 0 0 0 0 - 0 0
+1&7 +2&4 +3&4 +3&7 +4&7 +5&4 +9&4 + more than two 
diseases
1cellulitis - 0 0 1 2 0 0 0
2abscess 0 - 2 0 0 1 1 4
3osteomyelitis 1 3 - - 2 0 0 5
4staph.infection 0 - - 0 - - - 15
5endocarditis 0 0 0 0 0 - 0 5
6septic arthritis 0 0 0 0 0 0 0 0
7ulcer - 0 0 - - 0 0 2
8thrombophlebitis 0 0 0 0 0 0 0 0
9myositis 0 0 0 0 0 0 - 0
*According to ICD 10 codes. ICD 10 codes categorized into 9 diseases and listed from 1 to 9. First column refers to when disease listed as primary 
diagnosis. Other columns refer to multiple diseases reported, irrespective of whether event was primary, secondary, tertiary, quaternary, or 
quinary.
Table 3: Frequency of hospitalizations for a cutaneous injection-related infection or related infectious complication*.
Once Twice Three times Four times Five plus times Total
1cellulitis 19 7 3 0 2 59
2abscess 10 5 2 0 0 26
3osteomyelitis 5 2 2 0 3 39
4staph.infection 10 2 0 3 2 42
5endocarditis 11 0 1 0 1 24
6septic arthritis 6 3 0 0 0 12
7ulcer 1 0 1 0 1 6
8thrombophlebitis 1 0 1 0 0 4
9myositis 3 0 1 0 0 4
*According to ICD 10 codes. Diseases listed from 1 to 9. ICD 10 codes categorized into 9 diseases and listed from 1 to 9. Data relates to number 
of times an individual developed a disease, irrespective of whether event was coded as primary, secondary, tertiary, quaternary, or quinary.
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vents lengthy and expensive hospital visits for a CIRI or
related infectious complication. According to the cost
savings calculation based on the length of stay reduction,
SIF nurse referral resulted in a minimum saving of
C$2,136 per admission. However, it is important to note
that variability in treatment costs exists in the CIRI and
related infectious complications included in this investi-
gation.
Using the same cohort, the risk factors for the outcome
of developing a CIRI have been reported to include being
female, living in unstable housing, borrowing syringes,
requiring help injecting and injecting cocaine daily [20].
Some factors differ from risk factors in other cities. For
example, research from San Francisco reports an associ-
ated between developing a CIRI and frequent black tar
heroin injection [2] whereas in Vancouver, frequent
cocaine injection has been associated with developing a
CIRI [20]. The present study evaluated the predictors of
the outcome of hospitalization for a CIRI or related infec-
tious complication. The predictors of hospitalization for a
CIRI or related infectious complication included being
HIV positive and referred to the hospital by a nurse at the
SIF. Future research investigating outcomes, including
mortality from a CIRI or related infectious complication
among those referred compared to those not referred to
the hospital by a nurse at the supervised injection facility
would support our understanding of the potential impact
of nurse referral. Interestingly, being HIV positive was
not a risk factor for the development of CIRI but was a
predictor of hospitalization for a CIRI or related infec-
tious complication.
As noted above, an increased risk of hospitalization for
a CIRI or related infectious complication was observed
among HIV positive participants. This finding is consis-
tent with previous research on hospitalization among
IDU in this setting [1]. Individuals with HIV may be more
likely to be treated as an inpatient as opposed to an out-
patient (i.e., HIV positive patients with abscesses may be
more likely to get admitted to the hospital than HIV neg-
ative patients with abscesses). A potentially elevated sus-
ceptibility to bacterial infections [8,24] as well as known
high-risk drug injection practices in this subpopulation
[25,26] may related to why HIV positive participants in
this study had elevated rates of hospitalization. Further
elucidation of this finding with a larger sample of HIV
positive IDU is necessary to examine this important
research question.
After controlling for factors that are known to be asso-
ciated with hospitalization [1,27], referral from an SIF
nurse remained a strong predictor of hospitalization.
Findings from this study confirm existing qualitative
research indicating that nurses at the SIF provide CIRI-
related care and play a key role in enhancing access to
medical care among participants who have infections or
injuries of greater severity [28]. Hospital care for more
severe forms of CIRI is essential since local hospitals pro-
vide treatment to CIRI not available at the SIF (e.g., inci-
sion and drainage of an abscess, intravenous antibiotic
therapy as well as diagnostic tools and therapy appropri-
ate for complications). Further, given that the average
length of stay in hospital for those referred to the hospital
by a nurse at the SIF was significantly shorter, it may be
that nurses at the SIF are helping reduce the incidence of
late presentation of complications, such as osteomyelitis,
that are often lengthy and are particularly costly to the
healthcare system [7]. Although our study design does
not allow us to infer causation, it is noteworthy that this
association persisted in multivariate analyses. This may
reflect prompt referral as well as the preventative effect of
the SIF on serious infections [16].
There are several examples of efficient and cost effec-
tive community-based treatment services that may
inform changes in the provision of care that is required in
order to reduce the incidence of hospitalization of a CIRI
or related infectious complication in our setting. In its
first year of operation, the Integrated Soft Tissue Infec-
tion Services (ISIS) Clinic in San Francisco, California,
resulted in a 47% decrease in surgical service admissions
and an estimated savings of over $8.0 (C$8.4) million for
costs related to CIRI [29]. In addition, a wound manage-
ment clinic operated in conjunction with a syringe
exchange program in Oakland, California [30]. It was
found that the average cost per individual treated at this
wound management clinic was $5.0 (C$5.2), substantially
lower than equivalent hospital costs of $185.0 (C$193.4)
and $360.0 (C$376.3) [30]. Given the success other cities
have had in implementing additional medical treatment
for CIRI in the community, we recommend initiating pro-
vision of on-site incision and drainage for abscesses and
administration of antibiotic therapy at the SIF or in a
nearby community setting. Further, to prevent develop-
ment of CIRI, it may be of value to screen and treat for
MRSA at the SIF or at the SEOSI research site. In our set-
ting, expanding the capacity to provide primary care in an
integrated manner is warranted.
There are limitations of the present study to consider
when interpreting this data. Firstly, St. Paul's Hospital was
the only facility linkage that was conducted. However,
this is the primary hospital serving the SIF catchment
area and is accessed extensively by the IDU population in
the DTES [1,27,31]. Secondly, our study relies on self
report to obtain drug use and other behavioural variables.
However, self report among IDU is considered valid [32]
and hospital utilization and nurse referral were accessed
directly from databases within the hospital and at the SIF,
respectively. Thirdly, a limitation of this analysis is that a
low sample size of HIV positive participants precluded
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Additional research is required with a larger sample of
HIV positive individuals to better elucidate this finding.
Fourthly, additional research is required to better under-
stand why a shorter length of stay is seen among SEOSI
participants referred by a nurse at the SIF to the hospital.
It is possible that nurses may be referring to the hospital
SEOSI participants that require shorter lengths of stay
(e.g., abscess versus osteomyelitis). However, in our study,
individuals with an ED visit who were referred by a nurse
were significantly more likely to be hospitalized within
three days. Similarly, Binswanger et al. found ED use for
CIRI to be associated with hospitalization and also death
[33].
Conclusion
In summary, we found high levels of hospitalization for a
CIRI or related infectious complication among local IDU.
Being HIV positive and being referred to the hospital by a
nurse at the SIF, as opposed to self referral to the hospital,
were both independently and positively associated with
an increased likelihood of hospitalization. Participants
who had been referred to the hospital by a nurse at the
SIF had a significantly shorter length of stay in hospital as
compared to those who were not. These findings indicate
that nurses at the SIF play a critical role in terms of refer-
ring individuals who require hospitalization for a CIRI or
related infectious complication to the hospital, which
may result in shorter and less expensive hospital visits.
Expanded management of CIRI in the community may
reduce the need for referral to the hospital, further reduc-
ing the cost of caring for this common clinical problem
among IDU.
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Table 4: Univariate and multivariate Cox proportional hazard analyses of hospitalizations for a cutaneous injection-
related infection or related infectious complication among among Scientific Evaluation of Supervised Injection 
participants.
Unadjusted Adjusted
Hazard Ratio (HR) Hazard Ratio (AHR)
Variable HR (95% CI) p-value AHR (95% CI) p-value
Age
(per year older) 0.98 (0.96 - 1.01) 0.146
Sex
(Female vs Male) 1.59 (1.07 - 2.39) 0.024 1.36 (0.90 - 2.05) 0.139
Unstable housing*
(Yes vs No) 1.65 (1.08 - 2.53) 0.021 1.26 (0.79 - 2.02) 0.328
Cocaine injection*
(Daily vs Not daily) 1.75 (1.17 - 2.62) 0.006 1.46 (0.94 - 2.25) 0.090
Speedball injection*
(Daily vs Not daily) 1.90 (1.15 - 3.14) 0.012 1.19 (0.69 - 2.07) 0.528
HIV serostatus
(Positive vs Negative) 2.12 (1.39 - 3.24) <0.001 1.79 (1.16 - 2.75) 0.008
Hospital referral†
(Yes vs No) 2.41 (1.55 - 3.77) <0.001 5.38 (3.39 - 8.55) <0.001
*Behaviour refers to activities in the last 6 months. †Indicates data derived from SIF database and by a study nurse. CI = confidence interval.
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